COL19A1 and amyotrophic lateral sclerosis: From these results, authors propose that COL19A1 could be a useful prognostic biomarker for selecting a homogeneous group of patients for clinical trials and suggest that COL19A1 is likely a promising therapeutic target in ALS [28].